Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:HSGX

Histogenics (HSGX) Stock Price, News & Analysis

Histogenics logo

About Histogenics Stock (NASDAQ:HSGX)

Advanced Chart

Key Stats

Today's Range
$1.04
$1.07
50-Day Range
$0.16
$3.07
52-Week Range
$0.08
$1.43
Volume
1.21 million shs
Average Volume
9.06 million shs
Market Capitalization
$99.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive HSGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Histogenics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HSGX Stock News Headlines

Traphaco JSC TRA
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.tc pixel
See More Headlines

HSGX Stock Analysis - Frequently Asked Questions

Histogenics Corp (NASDAQ:HSGX) announced its quarterly earnings data on Thursday, August, 9th. The biotechnology company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.10.

Histogenics (HSGX) raised $60 million in an IPO on Wednesday, December 3rd 2014. The company issued 4,300,000 shares at a price of $13.00-$15.00 per share. Cowen and Company, Needham & Company and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Histogenics investors own include Interpace Biosciences (IDXG), Verastem (VSTM), Progenics Pharmaceuticals (PGNX), Novavax (NVAX), SCYNEXIS (SCYX), Ocular Therapeutix (OCUL) and OPKO Health (OPK).

Company Calendar

Last Earnings
8/09/2018
Today
8/29/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical Appliances & Supplies
Sub-Industry
N/A
Current Symbol
NASDAQ:HSGX
CIK
1372299
Fax
N/A
Employees
49
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.79)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$8.64 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-34.96%
Return on Assets
18.40%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.05
Quick Ratio
4.05

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.01) per share
Price / Book
-105.00

Miscellaneous

Outstanding Shares
94,599,000
Free Float
N/A
Market Cap
$99.33 million
Optionable
Not Optionable
Beta
3.10
10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:HSGX) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners